A CRITICAL REVIEW OF WITHANIA SOMNIFERA L. WITH SPECIAL REFERENCE TO ITS PHARMACOLOGICAL ACTIONS
International Journal of Drug Delivery Technology · 10.06.2026 · 16 (53s)
DOI: 10.25258/ijddt.16.53s.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 10.06.2026. Verfasst von Pratibha Tupe und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Withania somnifera L. Dunal, commonly known as Ashwagandha, is a member of the nightshade family Solanaceae. This plant holds significant pharmacological importance in the Indian subcontinent and has been a cornerstone of Ayurvedic and indigenous medicine for over 3,000 years. This review compiles the latest information on its phytochemical and pharmacological activities, derived from diverse methodologies and sources, including Ayurvedic texts and various literature. Studies have shown that Ashwagandha possesses a range of beneficial properties, such as antioxidant, anxiolytic, adaptogenic, memory-enhancing, antiparkinsonian, antivenom, anti-inflammatory and antitumor effects. Additionally, it has been studied for its immunomodulatory, hypolipidemic, antibacterial, cardiovascular protective, and sexual behavior enhancing properties, as well as its impact on tolerance and dependence. The biological activities of Withania somnifera L. are primarily linked to two key withanolides: Withaferin-A and Withanolide-D. Withaferin-A, in particular, has demonstrated the ability to induce apoptosis (programmed cell death) in cancer cells by disrupting the cellular mechanisms that support tumor growth and metastasis. Besides withanolides, Ashwagandha contains other bioactive constituents, including Withanosides, sitoindosides, steroidal lactones and alkaloids, all of which offer a broad spectrum of therapeutic potential. Various research groups globally have identified several molecular targets of Withania somnifera L., such as inhibiting the activation of nuclear factor kappa-B and promoting cancer cell apoptosis. This review underscores that Withania somnifera L. is a rich source of withanolides and other bioactive compounds, making it a promising candidate for treating various chronic diseases, given its minimal side effects observed in pre-clinical studies. The encouraging results suggest that Ashwagandha should be further investigated to confirm these findings and uncover additional therapeutic benefits.
Zitieren
APA
Tupe, P., & Somani, R. (2026). A CRITICAL REVIEW OF WITHANIA SOMNIFERA L. WITH SPECIAL REFERENCE TO ITS PHARMACOLOGICAL ACTIONS. International Journal of Drug Delivery Technology, 16(53s). https://doi.org/10.25258/ijddt.16.53s.9
Vancouver
Tupe P, Somani R. A CRITICAL REVIEW OF WITHANIA SOMNIFERA L. WITH SPECIAL REFERENCE TO ITS PHARMACOLOGICAL ACTIONS. International Journal of Drug Delivery Technology. 2026;16(53s). doi:10.25258/ijddt.16.53s.9
BibTeX
@article{Tupe2026,
author = {Tupe, Pratibha and Somani, Rakesh},
title = {A CRITICAL REVIEW OF WITHANIA SOMNIFERA L. WITH SPECIAL REFERENCE TO ITS PHARMACOLOGICAL ACTIONS},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {53s},
doi = {10.25258/ijddt.16.53s.9}
}
EUVIMED